TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02060188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Specified dose on specified days
Study: NCT02615691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITI
Description: Immune tolerance induction therapy
Study: NCT04401475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOC plus 15mg/kg EB05 IV
Description: Standard of care plus single IV infusion of 15mg/kg of EB05.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOC plus 15mg/kg EB05 IV
Description: Standard of care plus single IV infusion of 15mg/kg of EB05.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC plus Placebo IV
Description: Standard of care plus a single IV infusion of placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC plus Placebo IV
Description: Standard of care plus a single IV infusion of placebo.
Study: NCT04572841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous
Study: NCT03093870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Varlitinib)
Description: oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
Study: NCT04082676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine spinal
Description: In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine spinal
Description: In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
Study: NCT01477411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Description: The maximum dose of PA21 will be 15.0 g/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Description: The maximum dose of PA21 will be 15.0 g/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The maximum dosage of Digoxin will be 0.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The maximum dosage of Digoxin will be 0.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The maximum dosage of Digoxin will be 0.5 mg/day
Study: NCT01104337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment consisted of two matching placebo tablets three times a day.
Study: NCT02499328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069
Study: NCT01572662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: 40 mg/m2 by vein on Days -6 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
Study: NCT04637139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebicorvir (VBR)
Description: 300mg Vebicovir containing 2 µCi \[14C\]VBR.
Study: NCT00408616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grazax-R
Description: Grass tablet, 75.000 SQ per day for one year

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Grazax Placebo
Description: Grazax Placebo, 0 SQ tablet per day for one year
Study: NCT03640741

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
Study: NCT02671630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A community-based computerized cognitive training program
Description: The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
Study: NCT00965757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-614
Description: T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
Study: NCT01044537

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF-04937319 will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319
Description: The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
Study: NCT02747680

Intervention type: OTHER
Group type: OTHER
Intervention: hypoglycemia (low blood sugar) in MRI
Description: hypoglycemia (low blood sugar) in MRI

Intervention type: OTHER
Group type: OTHER
Intervention: hypoglycemia (low blood sugar) in MRI
Description: hypoglycemia (low blood sugar) in MRI
Study: NCT00873587

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest tube pull on inspiration
Description: Pull chest tube on Inspiration
Study: NCT02594956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no nasogastric tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube
Study: NCT00873587

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Expiration
Description: Pull chest tube on Expiration
Study: NCT01287351

Intervention type: DRUG
Intervention: extra-fine hydrofluoroalkane beclometasone dipropionate

Intervention type: DRUG
Intervention: extra-fine hydrofluoroalkane beclometasone dipropionate

Intervention type: DRUG
Intervention: Fluticasone propionate

Intervention type: DRUG
Intervention: Fluticasone propionate
Study: NCT03892915

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: evidence-based depression treatment
Description: We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9\>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
Study: NCT04016402

Intervention type: DEVICE
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Clinical transcranial magnetic stimulation administered as part of usual care for the study population
Study: NCT01115621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glutenfree diet during the first year of life
Description: Glutenfree diet during the first year of life
Study: NCT04656548

Intervention type: DEVICE
Intervention: HydroPICC
Description: PICC lines
Study: NCT00928005

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss diet
Description: The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss diet plus exercise
Description: The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
Study: NCT02314247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: 20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment.
Study: NCT03951415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor and Anti-PD-L1
Description: olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
Study: NCT00480311

Intervention type: OTHER
Intervention: WHODAS II (World Health Organization Disability Assessment Schedule II)
Description: To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
Study: NCT02499328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab (treme)
Description: tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab (treme)
Description: tremelimumab
Study: NCT01589120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video decision aid
Description: Video decision aid of the goals of care
Study: NCT03493503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Intravenous Salbutamol loading dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: 10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
Study: NCT01970150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS real
Study: NCT04151004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental cycling test (ICT)
Description: Incremental cycling test to volitional exhaustion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental cycling test (ICT)
Description: Incremental cycling test to volitional exhaustion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant load cycling test (CET)
Description: Constant load cycling test to volitional exhaustion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant load cycling test (CET)
Description: Constant load cycling test to volitional exhaustion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental respiratory muscle test (IncRMET)
Description: Incremental respiratory muscle test to volitional exhaustion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental respiratory muscle test (IncRMET)
Description: Incremental respiratory muscle test to volitional exhaustion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental quadriceps muscle test (IncQMT)
Description: Incremental quadriceps muscle test to volitional exhaustion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental quadriceps muscle test (IncQMT)
Description: Incremental quadriceps muscle test to volitional exhaustion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training like interventions
Description: Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
Study: NCT03997838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 1000 mg of VVZ-149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study: NCT04151004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training like interventions
Description: Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
Study: NCT02094469

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol
Description: Oral, Bid, 24 weeks
Study: NCT02229994

Intervention type: OTHER
Intervention: Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.
Description: Evaluation will be performed on a group of 200 patients deriving from 4 samples.~* From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~* From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment.
Study: NCT03324256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: energy drink
Description: 16 oz cold commercially-available energy drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: energy drink
Description: 16 oz cold commercially-available energy drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caffeinated drink
Description: 16oz cold commercially-available caffeinated drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy gum
Description: 2 pieces of commercially-available energy gum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo gum
Description: 2 pieces of commercially-available placebo gum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gum
Description: 2 pieces of commercially-available placebo gum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo gum
Description: 2 pieces of commercially-available placebo gum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo gum
Description: 2 pieces of commercially-available placebo gum
Study: NCT01768260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced external counterpulsation
Description: EECP is performed for 1 hours every day, for a total of 36 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Standard drug therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Standard drug therapy
Study: NCT01296841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collaborative Imaging
Description: Hardware and software communication tools to provide clinical care from a distance.
Study: NCT00758797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photoimmunotherapy
Description: DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
Study: NCT03324256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control drink
Description: 16oz cold control drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: 16oz cold control drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total sleep deprivation
Description: 24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
Study: NCT04778072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 25mg twice daily
Description: ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
Study: NCT03336840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin tablets
Description: 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProMetS probiotics powder
Description: 4g (2 strips) of ProMetS probiotics powder administered orally every night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Metformin tablets; 2. ProMetS probiotics powder
Description: 1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Study: NCT04471740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSF shunt diversion
Description: Clinical response to a CSF shunt insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSF shunt diversion
Description: Clinical response to a CSF shunt insertion
Study: NCT02601781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PPCI)
Description: Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffold (BVS ABSORB)
Description: BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
Study: NCT01070303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg eow or ew
Description: Adalimumab 40 mg by subcutaneous injection every other week or every week
Study: NCT05743543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block
Description: The block is performed with a nasoscope and the administration of a local anesthetic.
Study: NCT02502630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
Study: NCT02234115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Mesylate
Description: Subcutaneous injection of 50mg Leuprolide Mesylate
Study: NCT03131297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment by radiofrequency
Description: Radiofrequency might destroy fistula tract without lesion of anal sphincter.
Study: NCT03516799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
Study: NCT01834326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVPOME (autogenous ex vivo produced oral mucosa equivalent)
Description: EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: POM (Palatal oral mucosa)
Description: POM is a tissue graft harvested from the palate and surgically placed into the defect area
Study: NCT01478087

Intervention type: DEVICE
Group type: OTHER
Intervention: Mysorba
Description: Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.